2018 Payment Schedule Test Updates

The table below reflects Records of Decision associated with laboratory tests under the Laboratory Services Act in BC.

LSA ROD #

Approvals Granted

LSA2018-002

Repatriation of Thiopurine Metabolites (TM) testing to British Columbia from out-of-province/out-of-country, and addition of a new Provisional (P) fee item P92277 – Thiopurine Metabolites, to the Laboratory Services Outpatient Payment Schedule.

Effective May 1, 2018, the Ministry of Health (MOH) has approved the addition of Thiopurine Metabolites (TM) testing on a provisional (P) basis for a one year period. Testing will be restricted to Victoria General Hospital and is restricted to referrals from specialists prescribing thiopurine medications, and to patients with active inflammatory bowel disease and/or adverse effects thought to be due to thiopurine toxicity.

LSA2017-023

Repatriation of infliximab and anti-infliximab antibody testing from Alberta to British Columbia.

Effective May 1, 2018, the Ministry of Health (MOH) has approved the repatriation and funding of Infliximab (IFX) and anti-infliximab antibody (IFXA) testing on a provisional basis (P) for a one year period. IFX and IFXA testing will be restricted to St. Paul’s Hospital (SPH).